Central Pacific Bank Trust Division Raises Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Central Pacific Bank Trust Division raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 22.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 245 shares of the medical instruments supplier’s stock after acquiring an additional 45 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Becton, Dickinson and Company were worth $59,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Jennison Associates LLC boosted its stake in shares of Becton, Dickinson and Company by 4.9% during the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock valued at $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC boosted its stake in shares of Becton, Dickinson and Company by 2,086.7% during the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock valued at $12,853,000 after purchasing an additional 49,559 shares during the period. Franklin Street Advisors Inc. NC purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $11,998,000. Avity Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 3.5% during the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock valued at $40,257,000 after purchasing an additional 5,527 shares during the period. Finally, Caden Capital Partners LP boosted its stake in shares of Becton, Dickinson and Company by 26.7% during the fourth quarter. Caden Capital Partners LP now owns 83,417 shares of the medical instruments supplier’s stock valued at $20,340,000 after purchasing an additional 17,599 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $0.86 during trading hours on Friday, reaching $238.22. The stock had a trading volume of 712,860 shares, compared to its average volume of 1,416,546. The stock has a fifty day moving average of $236.66 and a 200 day moving average of $235.59. The stock has a market cap of $68.85 billion, a P/E ratio of 52.47, a price-to-earnings-growth ratio of 1.92 and a beta of 0.42. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.96 earnings per share. Sell-side analysts predict that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 30th. Investors of record on Monday, September 9th were given a $0.95 dividend. The ex-dividend date of this dividend was Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.60%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday. Raymond James cut their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Finally, Evercore ISI upped their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.